Farnesyl transferase inhibitors in the treatment of breast cancer

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.12, Iss.3, 2003-03, pp. : 413-421

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Farnesyl transferase inhibitors in clinical development

By Caponigro Francesco Casale Marina Bryce Jane

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 6, 2003-06 ,pp. : 943-954

Informa Healthcare

Access to resources Recommend Favorite

Farnesyl Transferase Inhibitors as Potential Anticancer Agents

Mini Reviews in Medicinal Chemistry, Vol. 18, Iss. 19, 2018-11 ,pp. : 1611-1623

Bentham Science Publishers

Access to resources Recommend Favorite

Tipifarnib, a farnesyl transferase inhibitor, appears to have potential for patients with locally advanced breast cancer

Inpharma, Vol. 1, Iss. 1620, 2008-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Controlled Exploration of Structural Databases: The Case of Farnesyl Transferase Inhibitors

Medicinal Chemistry, Vol. 5, Iss. 3, 2009-05 ,pp. : 208-215

Bentham Science Publishers

Access to resources Recommend Favorite

Aromatase Inhibitors in the Treatment of Postmenopausal Breast Cancer

By Bajetta E.

Drugs & Aging, Vol. 15, Iss. 4, 1999-10 ,pp. : 271-283

Adis International

Access to resources Recommend Favorite